Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 17, 2013 16:15 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics Closes Public Offering of Common Stock

CHICAGO, April 17, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced the closing of its public offering of 8,222,500 shares of common stock at a public offering price of...
April 12, 2013 07:30 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics Prices Public Offering of Common Stock

CHICAGO, April 12, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced the pricing of an underwritten public offering of 7,150,000 shares of its common stock at a public...
April 02, 2013 15:30 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics to Host Reimbursement Seminar on April 23, 2013

CHICAGO, April 2, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced that it will host a reimbursement seminar for the investment community on Tuesday, April 23, 2013 at...
March 08, 2013 07:00 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics, Inc. Reports Full-Year 2012 Financial Results

CHICAGO, March 8, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced financial results for the year ended December 31, 2012. "2012 was a great year for Durata. We...
March 05, 2013 16:30 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics to Announce Full Year 2012 Financial Results on Friday, March 8, 2013

CHICAGO, March 5, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) has scheduled its quarterly conference call for Friday, March 8, 2013 at 8:30 a.m. Eastern Time to discuss full year 2012...
February 25, 2013 07:00 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics Announces Preliminary, Topline Phase 3 Clinical Trial Results for Dalbavancin in the Treatment of ABSSSI

DISCOVER 2 Study Meets Primary & Secondary Endpoints Conference Call and Webcast Today at 8:30 A.M. EST to Discuss Results CHICAGO, Feb. 25, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics,...
February 20, 2013 14:00 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics to Present at the Cowen & Company 33rd Annual Health Care Conference

CHICAGO, Feb. 20, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) today announced that Durata's Chief Executive Officer Paul R. Edick will present an overview of the company at the Cowen...
February 13, 2013 16:00 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics to Present at the 2013 RBC Capital Markets' Global Healthcare Conference

CHICAGO, Feb. 13, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics (Nasdaq:DRTX) today announced the company will participate in the RBC Capital Markets' Global Healthcare Conference scheduled for...
January 04, 2013 08:30 ET | Source: Durata Therapeutics, Inc.

Durata Therapeutics Meets Primary Endpoints for EMA Review in Phase 3 Clinical Trial

CHICAGO, Jan. 4, 2013 (GLOBE NEWSWIRE) -- Durata Therapeutics, Inc. (Nasdaq:DRTX) today announced additional preliminary, top-line results for its DISCOVER 1 ("Dalbavancin for Infections of the Skin...